BIVIGAM Recall

On April 2, 2013, the FDA issued an urgent recall for BIVIGAM Immune Globulin Intravenous, 10 percent liquid, 100 mL sterile vial due to visible particles observed in the liquid.  The recalled products are from lot# 120016 with an expiration date of March 31, 2014.  BIVIGAM is made by Biotest Pharmaceuticals and is used to treat primary immune deficiency.…
Continue reading...

Food & Drug Administration Admits It Could

Food & Drug Administration (FDA) Commissioner Margaret Hamburg testified before the U.S. House Energy and Commerce Committee’s Oversight panel about the agency’s actions leading up to the outbreak of meningitis that was linked to a compounding pharmacy last year and admitted that she regretted that the FDA did not do more and was not more directly engaged. She also acknowledged that the FDA had stopped conducting routine inspections of compounders as it developed a guidance documents for their regulation.  The FDA had stopped inspections because…
Continue reading...

A Potential Godsend to Mothers-to-Be

After a 30-year hiatus, the Food and Drug Administration (FDA) has once again approved a drug to specifically treat morning sickness.  Diclegis, made by Canadian Duchesnay Inc., is scheduled to be available in June 2013.  Diclegis combines Vitamin B6 and antihistamine doxylamine in a time released formula to prevent nausea before it sets in. The same drug combination was marketed as Benedectin from the 1950’s to 1980’s.  Despite no conclusive medical evidence that it caused birth defects and court rulings in its favor, Merrell Dow…
Continue reading...

Food & Drug Administration – Only 113 Characters Left In the Tweet

The FDA is on its way to regulating social media and its use by pharmaceutical companies.  By July 2014, the FDA must publish its guidelines for social media use. The FDA is faced with issuing guidelines on the appropriateness of tweeting.  A 140 character tweet is likely not long enough to include all of the necessary information such as risks and side effects.  Thomas Abrams, director of the FDA’s Office of Prescription Drug Promotion supports pharmaceutical companies promoting their products on Twitter if they can…
Continue reading...